In first individual cases, iRIT with [¹⁷⁷Lu]Lu-6A10-Fab appears to be feasible and safe, without therapy-related side effects. A confirmatory multicenter phase-I-trial was recently opened and is currently recruiting.
No takes yet. Share an insight, caveat, or question.
Anna Uhl Chamot (1987) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: